+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

KOL Perspectives: IL-6 inhibitors in Rheumatoid Arthritis

  • PDF Icon


  • 29 Pages
  • February 2018
  • Region: Global
  • GlobalData
  • ID: 4655559
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

KOL Perspectives: IL-6 inhibitors in Rheumatoid Arthritis


This KOL Insight briefing focuses on perceptions of IL-6 inhibitors in rheumatoid arthritis (RA).

The briefing includes analysis of KOL opinion on the following topic areas:
  • Current or anticipated future use of sarilumab in RA

  • Current use of tocilizumab in RA

  • Expected future change to sarilumab & tocilizumab use

  • Comparison of sarilumab & tocilizumab clinical profile in RA

  • Non-clinical differentiating factors between sarilumab & tocilizumab

  • Impact of and factors contributing to sirukumab discontinuation in RA

  • IL-6 inhibitors vs. JAK inhibitors in RA

  • KOL awareness of olokizumab currently in development for RA

Key Highlights:
  • Majority of US but not EU patients have access to sarilumab, with KOLs primarily positioning sarilumab in MTX-IR patients or after anti-TNFs

  • Most KOLs position tocilizumab after anti-TNFs, partly due to payer pressure, with first-line use possible in MTX-IR or ineligible patients

  • In the next 12 months, most KOLs expect an increase in use of sarilumab, and a reduction in use of tocilizumab.

  • The briefing is based on Sociable Pharma’s analysis of primary research with our RA key opinion leaders (KOLs)

  • In total, we conducted interviews with 10 KOLs: Five Europe-based & five US-based

  • Interviews performed in December 2017

  • KOL data is analyzed to produce: Charts summarizing KOL opinions

  • Chart call-outs of key information & details

  • KOL quotes

  • Summary of KOL reporting trends

  • Insight from Sociable Pharma's analysts.

Reasons to buy
  • Combines Qualitative & semi-quantitative insight from key opinion leaders on "IL-6 inhibitors in Rheumatoid Arthritis"

  • Includes insight & recommendations from our disease-specific healthcare analysts

  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of rheumatoid arthritis

  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Table of Contents

Executive Summary
Research Panel Composition
Results & Implications

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Sanofi
  • Roche
  • Genentech
  • UCB
  • GSK